Wolfe Research Upgrades Merck Stock Target Following Positive Cancer Drug Trial Results

Investment analysts have raised their price targets for Merck shares after clinical data demonstrated promising efficacy for the company's oncology pipeline, boosting investor confidence.

Post Share

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

Yahooilo8h ago

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Read full article →

investing-comFrench12h ago

Wolfe Research raises Merck stock price target on cancer drug data

Read full article →

Coverage Timeline

First report: investing-com · 25 Aug, 10:24|Full coverage: 2 · 4h|Window: 4h

Left-leaningCenterRight-leaning

investing-com25 Aug, 10:24First to report

Wolfe Research raises Merck stock price target on cancer drug data

4h later

Yahoo25 Aug, 14:21Latest update

PERSPECTA

PERSPECTA

Wolfe Research Upgrades Merck Stock Target Following Positive Cancer Drug Trial Results

Sources

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Wolfe Research raises Merck stock price target on cancer drug data

Coverage Timeline

Wolfe Research raises Merck stock price target on cancer drug data

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Related Stories

Par Pacific to Sell Laramie Energy Assets for $485 Million

Multiple Company Executives Sell Significant Shares in Their Respective Firms

Box Reports Strong Q2 2026 Revenue, Lifts Full-Year Outlook

Franklin Templeton and Franklin Can Low Volatility ETF Announce Dividends

PERSPECTA